The Clostridium botulinum C2 Toxin Subunit C2IIa Delivers Enzymes with Positively Charged N-Termini into the Cytosol of Target Cells

Toxins (Basel). 2023 Jun 9;15(6):390. doi: 10.3390/toxins15060390.

Abstract

The binary Clostridium (C.) botulinum C2 toxin consists of two non-linked proteins. The proteolytically activated binding/transport subunit C2IIa forms barrel-shaped homoheptamers, which bind to cell surface receptors, mediate endocytosis, and translocate the enzyme subunit C2I into the cytosol of target cells. Here, we investigate whether C2IIa can be harnessed as a transporter for proteins/enzymes fused to polycationic tags, as earlier demonstrated for the related anthrax toxin transport subunit PA63. To test C2IIa-mediated transport in cultured cells, reporter enzymes are generated by fusing different polycationic tags to the N- or C-terminus of other bacterial toxins' catalytic A subunits. C2IIa as well as PA63 deliver N-terminally polyhistidine-tagged proteins more efficiently compared to C-terminally tagged ones. However, in contrast to PA63, C2IIa does not efficiently deliver polylysine-tagged proteins into the cytosol of target cells. Moreover, untagged enzymes with a native cationic N-terminus are efficiently transported by both C2IIa and PA63. In conclusion, the C2IIa-transporter serves as a transport system for enzymes that harbor positively charged amino acids at their N-terminus. The charge distribution at the N-terminus of cargo proteins and their ability to unfold in the endosome and subsequently refold in the cytosol determine transport feasibility and efficiency.

Keywords: C2IIa; Clostridium botulinum C2 toxin; bacterial AB-type protein toxins; cytosolic drug delivery; molecular Trojan horse; polyhistidine-tag; protective antigen (PA).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Botulinum Toxins* / chemistry
  • Cytosol / metabolism
  • Endocytosis
  • Endosomes / metabolism

Substances

  • botulinum toxin type C
  • Botulinum Toxins

Grants and funding

This research was funded by the German Research Foundation (DFG) and Medical Faculty Ulm. The DFG supported this work as part of the CRC 1279 (C02)—Project number 316249678—SFB 1279 and as part of the CRC 1149 (A05)—Project number 251293561—SFB 1149. The Medical Faculty Ulm supported this work as part of the Baustein funding (Baustein 3.2 to Stephan Fischer). Joscha Borho, Sebastian Heber, Nicole Stadler, and Irina König are members of the International Graduate School in Molecular Medicine Ulm (IGradU) and gratefully thank the IGradU for its kind support.